| 1.1 Pain intensity (VAS) |
8 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.1.1 Immediately after |
7 |
1403 |
Mean Difference (IV, Random, 95% CI) |
‐9.22 [‐13.82, ‐4.61] |
| 1.1.2 Short term |
5 |
1095 |
Mean Difference (IV, Random, 95% CI) |
‐10.04 [‐17.22, ‐2.85] |
| 1.1.3 Intermediate term |
4 |
1138 |
Mean Difference (IV, Random, 95% CI) |
‐3.83 [‐6.57, ‐1.09] |
| 1.2 Back‐specific function |
5 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.2.1 Immediately after (RMDQ, ODI, HFAQ) |
5 |
1481 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.16 [‐0.38, 0.06] |
| 1.2.2 Short term (ODI, HFAQ) |
3 |
957 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.38 [‐0.69, ‐0.07] |
| 1.2.3 Intermediate term (RMDQ, ODI, HFAQ) |
4 |
1373 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.16 [‐0.27, ‐0.05] |
| 1.3 Quality of life |
2 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.3.1 Immediately after (SF‐36) |
2 |
157 |
Mean Difference (IV, Random, 95% CI) |
4.42 [‐1.34, 10.18] |
| 1.4 Quality of life |
3 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.4.1 Short term (SF‐36, SF‐12 physical) |
3 |
1068 |
Std. Mean Difference (IV, Random, 95% CI) |
0.24 [0.03, 0.45] |
| 1.4.2 Intermediate term (SF‐36, SF‐12 physical) |
3 |
1066 |
Std. Mean Difference (IV, Random, 95% CI) |
0.21 [0.09, 0.33] |
| 1.5 Pain‐related disability (PDI) |
2 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.5.1 Immediately after |
2 |
285 |
Mean Difference (IV, Random, 95% CI) |
‐3.28 [‐6.39, ‐0.17] |
| 1.5.2 Intermediate term |
2 |
269 |
Mean Difference (IV, Random, 95% CI) |
‐2.91 [‐6.33, 0.51] |
| 1.6 Global assessment of therapy effectiveness (6‐point scale) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.6.1 Immediately after |
1 |
744 |
Mean Difference (IV, Random, 95% CI) |
‐0.30 [‐0.49, ‐0.11] |
| 1.6.2 Short term |
1 |
747 |
Mean Difference (IV, Random, 95% CI) |
‐0.30 [‐0.49, ‐0.11] |
| 1.6.3 Intermediate term |
1 |
751 |
Mean Difference (IV, Random, 95% CI) |
‐0.20 [‐0.39, ‐0.01] |
| 1.7 Global assessment of therapy effectiveness (effective number) |
3 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.7.1 Immediately after |
2 |
163 |
Risk Ratio (M‐H, Random, 95% CI) |
1.23 [1.04, 1.46] |
| 1.7.2 Short term |
2 |
141 |
Risk Ratio (M‐H, Random, 95% CI) |
1.88 [0.66, 5.36] |
| 1.8 Adverse events |
4 |
465 |
Risk Ratio (M‐H, Random, 95% CI) |
0.68 [0.46, 1.01] |
